- ISIN
- US56600D1072
- CUSIP
- 56600D107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 20, 2020
Highlights
- Market Cap
- $708.70M
- Enterprise Value
- $583.53M
- EPS (TTM)
- -$0.72
- Total Revenue (TTM)
- $204.73M
- Gross Profit (TTM)
- $59.37M
- EBITDA (TTM)
- -$118.27M
- Year Range
- $1.99 - $5.00
- Target Price
- $5.25
- ROA (TTM)
- -14.66%
- ROE (TTM)
- -49.42%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MRVI Performance Chart
Maravai LifeSciences Holdings, Inc. (MRVI) is up 48.9% since the beginning of the year. At $5 per share, MRVI is trading 3.1% below its 52-week high of $5. Investors who bought $1,000 worth of MRVI shares 5 years ago would now be looking at an investment worth $113.
Loading charts...
Returns By Period
Maravai LifeSciences Holdings, Inc. (MRVI) has returned 48.92% so far this year and 118.02% over the past 12 months.
Maravai LifeSciences Holdings, Inc.
- 1D
- 0.21%
- 1M
- 27.70%
- YTD
- 48.92%
- 6M
- 37.89%
- 1Y
- 118.02%
- 3Y*
- -28.66%
- 5Y*
- -35.31%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
MRVI Monthly Returns History
Based on dividend-adjusted daily data since Nov 20, 2020, MRVI's average daily return is -0.03%, while the average monthly return is -1.17%.
Historically, 41% of months were positive and 59% were negative. The best month was Jul 2024 with a return of +35.9%, while the worst month was Oct 2022 at -35.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, MRVI closed higher 48% of trading days. The best single day was Feb 23, 2024 with a return of +63.6%, while the worst single day was Nov 8, 2024 at -35.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.38% | 5.95% | -20.51% | 30.04% | 30.43% | 0.83% | 48.92% | ||||||
| 2025 | -9.54% | -34.69% | -31.37% | -8.60% | 11.39% | 7.11% | -2.90% | 3.42% | 18.60% | 9.41% | 15.29% | -10.22% | -40.37% |
| 2024 | -11.45% | 33.28% | 12.16% | -5.42% | 5.73% | -17.42% | 35.89% | -6.99% | -8.18% | -10.83% | -23.48% | -3.88% | -16.79% |
| 2023 | 2.45% | 0.61% | -5.02% | -1.57% | -6.89% | -3.19% | -9.01% | -8.58% | -3.29% | -31.40% | -25.66% | 28.43% | -54.23% |
| 2022 | -30.98% | 35.10% | -9.73% | -12.87% | 1.37% | -8.80% | -8.17% | -20.01% | 22.33% | -34.98% | -10.36% | -3.83% | -65.85% |
| 2021 | 24.21% | -6.66% | 9.59% | 9.18% | -3.52% | 11.16% | 5.37% | 34.59% | -17.07% | -13.83% | 8.63% | -8.79% | 49.38% |
Benchmark Metrics
Maravai LifeSciences Holdings, Inc. has an annualized alpha of -20.92%, beta of 1.12, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since November 23, 2020.
- This stock participated in 183.93% of S&P 500 Index downside but only 15.03% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -20.92%
- Beta
- 1.12
- R²
- 0.06
- Upside Capture
- 15.03%
- Downside Capture
- 183.93%
Return for Risk
Risk / Return Rank
MRVI ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Maravai LifeSciences Holdings, Inc. (MRVI) and compare them to S&P 500 Index.
| MRVI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.61 | ||
| Sortino ratioReturn per unit of downside risk | -0.51 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.41 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | 3.97 | 2.93 | +1.04 |
| Martin ratioReturn relative to average drawdown | 8.88 | 13.52 | -4.64 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Maravai LifeSciences Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Maravai LifeSciences Holdings, Inc. was 97.16%, occurring on Apr 16, 2025. The portfolio has not yet recovered.
The current Maravai LifeSciences Holdings, Inc. drawdown is 92.02%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.16%Apr 2025 | 3y 7mo | — | 4y 9moAug 2021 - now |
2021 correction2021 | -18.22%Jul 2021 | 1mo 1d | 18d | 1mo 19dJun 2021 - Aug 2021 |
2020 correction2020 | -17.92%Dec 2020 | 16d | 9d | 25dNov 2020 - Dec 2020 |
2021 correction2021 | -16.78%Mar 2021 | 13d | 1mo 2d | 1mo 15dMar 2021 - Apr 2021 |
2021 correction2021 | -16.40%Jan 2021 | 14d | 16d | 1moDec 2020 - Jan 2021 |
Drawdown Indicators
| MRVI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.16% | -56.78% | -40.38% |
Max Drawdown (1Y)Largest decline over 1 year | -29.93% | -9.10% | -20.83% |
Max Drawdown (3Y)Largest decline over 3 years | -88.25% | -18.90% | -69.35% |
Max Drawdown (5Y)Largest decline over 5 years | -97.16% | -25.43% | -71.73% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.02% | -0.74% | -91.28% |
Average DrawdownAverage peak-to-trough decline | -67.60% | -10.72% | -56.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.34% | 1.97% | +11.37% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Maravai LifeSciences Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Maravai LifeSciences Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MRVI relative to other companies in the Biotechnology industry. Currently, MRVI has a P/S ratio of 3.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MRVI in comparison with other companies in the Biotechnology industry. Currently, MRVI has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MRVI
Add Maravai LifeSciences Holdings, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MRVI